Bhaskar Chaudhuri - 12 Jun 2026 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Reporting relationship: Director
Issuer ticker: TARS
Reported as of: 12 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Jun 2026, 16:06:13 UTC
Prior SEC filing: 16 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Jeffrey Farrow, Attorney-in-Fact

Key filing fact

Bhaskar Chaudhuri filed Form 4 for Tarsus Pharmaceuticals, Inc. (TARS) on 16 Jun 2026.

Key facts

This page summarizes Bhaskar Chaudhuri's Form 4 filing for Tarsus Pharmaceuticals, Inc. (TARS).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 16 Jun 2026, 16:06.

Change

Previous filing in this sequence was filed on 16 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001458643 Primary reporting owner

CHAUDHURI BHASKAR

Relationship: Director
Address: C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE
Signature: /s/ Jeffrey Farrow, Attorney-in-Fact
Signature date: 16 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TARS transaction

Common Stock

Options Exercise

Transaction value
Shares: +2,954
Change %: +34%
Price
Shares after: 11,654
Date: 12 Jun 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TARS transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -2,954
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 12 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,954
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.

Footnote F2

Each RSU represents a contingent right to receive one share of the Company's common stock.

Footnote F3

RSUs granted on June 12, 2025, in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.